COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations (CHOICE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00184795
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : February 23, 2017
Information provided by (Responsible Party):
Novo Nordisk A/S

Brief Summary:
This trial is conducted in Europe. Postmenopausal women with moderate to severe hot flashes have been recruited into the trial. The earliest effect of ultra low dose HRT (hormone replacement therapy) on frequency and severity of menopausal symptoms, bleeding patterns and safety of different hormonal combinations will be evaluated and compared to placebo over the six month treatment period.

Condition or disease Intervention/treatment Phase
Menopause Menopausal Vasomotor Symptoms Drug: 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) Drug: 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) Drug: placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 576 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Six Month Double-blind, Randomised, Parallel-group, Placebo-controlled, Multi-centre Trial to Investigate the Efficacy and Safety of Two Ultra-low Dose Combinations With 0.5 mg Estradiol and 0.1 mg or 0.25 mg Norethisterone Acetate (Activelle Low Dose 0.1/Activelle Low Dose 0.25) for Treatment of Menopausal Symptoms
Actual Study Start Date : May 28, 2004
Actual Primary Completion Date : May 4, 2005
Actual Study Completion Date : May 4, 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Menopause
Drug Information available for: Estradiol

Arm Intervention/treatment
Experimental: ALD 0.1 Drug: 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)
One tablet per day for 24 weeks

Experimental: ALD 0.25 Drug: 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)
One tablet per day for 24 weeks

Placebo Comparator: Placebo Drug: placebo
Placebo tablets for 24 weeks

Primary Outcome Measures :
  1. Change in mean number of moderate to severe hot flushes per week [ Time Frame: At week 8 ]

Secondary Outcome Measures :
  1. Urogenital symptoms [ Time Frame: Week 0; week 24 ]
  2. Vaginal cytology and pH [ Time Frame: Week 0; week 24 ]
  3. Bleeding profile [ Time Frame: Week 0; week 24 ]
  4. Adverse Events [ Time Frame: Week 0; week 24 ]
  5. Menopausal symptoms and quality of life (Greene Climacteric Scale) [ Time Frame: Week 0; week 24 ]
  6. Hot flush weekly weighted score [ Time Frame: Week 0; week 24 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Postmenopausal status
  • Subject should have had a minimum of 7 moderate to severe hot flushes per day, or a minimum of 50 moderate to severe hot flushes per week, during the last 2 weeks of the run-in (screening) period.
  • Subject with an intact uterus

Exclusion Criteria:

  • In accordance with existing labelling for estrogen/progestogen combinations
  • Body Mass Index (BMI) > 35.0 kg/m2
  • Known alcohol or drug abuse, heavy smoking (more than 20 cigarettes a day)
  • Currently using steroid hormones (except topical or inhalation glucocorticoid preparations) and drugs known to influence estrogen metabolism such as barbiturates, phenytoin, rifampicin, carbamazepin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00184795

Show Show 92 study locations
Sponsors and Collaborators
Novo Nordisk A/S
Layout table for investigator information
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: Novo Nordisk A/S Identifier: NCT00184795    
Other Study ID Numbers: ALD-1537
2004-000103-17 ( EudraCT Number )
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: February 23, 2017
Last Verified: February 2017
Keywords provided by Novo Nordisk A/S:
Hot flashes
Additional relevant MeSH terms:
Layout table for MeSH terms
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Norethindrone Acetate
Polyestradiol phosphate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents
Reproductive Control Agents
Contraceptive Agents, Female
Contraceptives, Oral, Synthetic
Contraceptives, Oral